Close

COVID-19 vaccine : Bharat Biotech to provide 55 lakh Covaxin doses at Rs 295 per dose

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

ACHEMA 2027 Strengthens India Process Industry Collaboration

DECHEMA, EEPC INDIA and Messe Frankfurt India brought together...

Onyx Scientific Boosts API Manufacturing Capacity in UK

Onyx Scientific, a global small molecule CDMO, is investing...

Strengthening Supply Chain Visibility for Safe Medicines

A comprehensive survey of 5,000 patients across the United...
- Advertisement -

Bharat Biotech inked a purchase agreement with the Government of India on January 11 to provide 55 lakh doses of COVID-19 vaccine Covaxin at Rs 295 per dose.

The Indian pharma firm will be providing its coronavirus vaccine directly to 12 states, and the process will be completed in two days by January 14. Dispatches will begin from Hyderabad starting January 12, the report said.

Bharat Biotech will be providing 38.5 lakh doses of the COVID-19 vaccine in stage 1 and 16.5 doses in stage 2. Each single-dose vial will cost around Rs 295 plus taxes, which means each shot of Covaxin will cost around Rs 310.

Earlier in the day, the Serum Institute of India (SII) secured a purchase order for Oxford-AstraZeneca’s Covishield coronavirus vaccine from the Indian government.

Oxford-AstraZeneca’s COVID-19 vaccine Covishield, which is being manufactured by SII in India, will be available for Rs 220 per vial (inclusive of 14 percent GST) in India. The Centre has inked a deal to procure 11 million doses of the SII COVID-19 vaccine for the massive coronavirus vaccine rollout that is set to begin from January 16.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

ACHEMA 2027 Strengthens India Process Industry Collaboration

DECHEMA, EEPC INDIA and Messe Frankfurt India brought together...

Onyx Scientific Boosts API Manufacturing Capacity in UK

Onyx Scientific, a global small molecule CDMO, is investing...

Strengthening Supply Chain Visibility for Safe Medicines

A comprehensive survey of 5,000 patients across the United...

Novo Nordisk and Orbis Medicines Partner on Oral Therapies for Cardiometabolic Diseases

Danish pharmaceutical company Novo Nordisk and biotechnology developer Orbis...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »